021-51111890
购物车（）
sales@molnova.cn
Olcegepant
CAS No. 204697-65-4
Olcegepant ( BIBN-4096;BIBN-4096BS;BIBN4096BS )
产品货号. M13181 CAS No. 204697-65-4
The first small molecule selective CGRP antagonist with Ki of 14.4 nM for hCGRP.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥381 | 有现货 |
|
| 5MG | ￥786 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Olcegepant
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述The first small molecule selective CGRP antagonist with Ki of 14.4 nM for hCGRP.
-
产品描述The first small molecule selective CGRP antagonist with Ki of 14.4 nM for hCGRP; inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys (1-30mg/kg, i.v.).
-
同义词BIBN-4096;BIBN-4096BS;BIBN4096BS
-
通路GPCR/G Protein
-
靶点CGRP Receptor
-
受体CGRP Receptor
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number204697-65-4
-
分子量869.65
-
分子式C38H47Br2N9O5
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 50 mg/mL
-
SMILESO=C(N1CCC(N2C(NC3=C(C=CC=C3)C2)=O)CC1)N[C@H](CC4=CC(Br)=C(O)C(Br)=C4)C(N[C@H](C(N5CCN(C6=CC=NC=C6)CC5)=O)CCCCN)=O
-
化学全称Piperazine, 1-[3,5-dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Doods H, et al. Br J Pharmacol. 2000 Feb;129(3):420-3.
2. Powell KJ, et al. Br J Pharmacol. 2000 Nov;131(5):875-84.
3. Edvinsson L, et al. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53.
2. Powell KJ, et al. Br J Pharmacol. 2000 Nov;131(5):875-84.
3. Edvinsson L, et al. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53.
产品手册
关联产品
-
PHM 27 (human)
Endogenous peptide product of human prepro-VIP and analog of porcine PHI-27; potent agonist for the human calcitonin receptor (EC50 = 11 nM). Transgenic mice expressing the human VIP/PHM 27 gene in pancreatic β-islets display enhanced glucose-induced insulin secretion.
-
Calcitonin（salmon） A...
Calcitonin（salmon） Acetate, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period.
-
MK-0974
A potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 0.77 nM.
